Compare ADMA Biologics Inc (ADMA) vs DoorDash Inc (DASH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs DoorDash Inc — how do they compare? ADMA Biologics Inc trades at $9.25 (market cap $2.13B), while DoorDash Inc trades at $184.84 (market cap $85.28B). The key difference: DoorDash Inc is far larger — about 40× ADMA Biologics Inc's market cap, and DoorDash Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | DASH | |
|---|---|---|
Market Cap | $2.13B | $85.28B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $281.74 |
52-Week Low | $7.60 | $146.60 |
Enterprise Value | $2.20B | $83.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
DoorDash (DASH) trades at $195.72, up 1.93% today, with a bullish technical signal and strong analyst consensus. Revenue grew to $13.72B in 2025, with net income reaching $935M, though recent quarters show mixed earnings performance. The stock is near resistance at $200, with RSI indicating overbought conditions. Recent news highlights AI initiatives and market dominance.
Outlook remains positive with a $231.50 consensus price target, but risks include competition and high valuation multiples. Earnings growth and international expansion are key catalysts, while inflation and execution challenges pose headwinds for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About DoorDash Inc
Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).
Read more on DASH →
